Castle Biosciences Inc Stock News

FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2025, after the close of market on Monday, Nov. 3, 2025.

FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded the CEO of the Year by The CEO Magazine. The Executive of the Year Awards program recognizes senior executives driving me...

FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized as a Greater Pittsburgh Top Workplace by The Pittsburgh Post-Gazette.

FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America's Greatest Companies list, published by Newsweek.

FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data demonstrating the personalized risk stratification provided by its TissueCypher Barrett's Esophagus test will be shared via a podium presentation at the American Foregut Society's (AFS) 2025 Ann...

Castle Biosciences effectively translates complex diagnostics into a scalable, high-margin business, with strong clinical demand and a robust balance sheet supporting long-term growth. The investment thesis centers on margin expansion and payer coverage; current valuation does not reflect the company's profit potential or future margin upside. Key risks include reimbursement uncertainty for Dec...

New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms test results align with treatment decision-making thresholds for adjuvant radiation therapy and surveillance imaging FRIENDSWOOD, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (...

FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at Baird's 2025 Global Healthcare Conference on Wednesday, Sept. 10, 2025, at 10:15 a.m.